13G Filing: Jim Tananbaum’s Foresite Capital Buys More Shares of Aerie Pharmaceuticals Inc (AERI)

ITEM 1(A).

NAME OF ISSUER

Aerie Pharmaceuticals, Inc. (the “Issuer”)

ITEM 1(B).

ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

2030 Main Street, Suite 1500

Irvine, California 92614

ITEM 2(A).

NAME OF PERSONS FILING

This Schedule is filed by Foresite Capital Fund II, L.P., a Delaware limited partnership, Foresite Capital Management II, LLC, a Delaware limited liability company, Foresite Capital Fund III, L.P., a Delaware limited partnership, Foresite Capital Management III, LLC, a Delaware limited liability company and James Tananbaum. The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

ITEM 2(B).

ADDRESS OF PRINCIPAL OFFICE

The address for each of the Reporting
Persons is:

c/o Foresite Capital Management

101 California Street, Suite 4100
San Francisco, CA 94111

ITEM 2(C).

CITIZENSHIP

See Row 4 of cover page for each Reporting Person.

ITEM 2(D).

TITLE OF CLASS OF SECURITIES

Common Stock

ITEM 2(D)

CUSIP NUMBER

00771V108

ITEM 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

ITEM 4.

OWNERSHIP

The following information with respect
to the ownership of the common stock of the Issuer by the persons filing this Statement is provided as of February 18, 2016: